Investment Analysts’ Weekly Ratings Updates for Lexicon Pharmaceuticals (LXRX)

A number of firms have modified their ratings and price targets on shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) recently:

• 11/5/2024 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
• 10/30/2024 – Lexicon Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 10/30/2024 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 10/23/2024 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 10/18/2024 – Lexicon Pharmaceuticals was given a new $6.00 price target on by analysts at Leerink Partners. They now have an “outperform” rating on the stock.
• 10/17/2024 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 10/3/2024 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 9/27/2024 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 9/11/2024 – Lexicon Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

Lexicon Pharmaceuticals Trading Down 2.3 %

Shares of LXRX stock traded down $0.03 during trading hours on Friday, reaching $1.27. 2,932,420 shares of the stock were exchanged, compared to its average volume of 3,483,904. The company has a current ratio of 11.51, a quick ratio of 11.49 and a debt-to-equity ratio of 0.41. Lexicon Pharmaceuticals, Inc. has a 12-month low of $0.92 and a 12-month high of $3.73. The firm has a market capitalization of $312.72 million, a price-to-earnings ratio of -1.63 and a beta of 1.24. The company’s 50-day moving average price is $1.67 and its 200-day moving average price is $1.75.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several hedge funds have recently made changes to their positions in LXRX. BNP Paribas Financial Markets boosted its position in Lexicon Pharmaceuticals by 82.6% during the 1st quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 26,859 shares in the last quarter. Vanguard Group Inc. boosted its position in Lexicon Pharmaceuticals by 7.0% during the first quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock valued at $15,363,000 after purchasing an additional 420,854 shares in the last quarter. Boulder Hill Capital Management LP purchased a new position in Lexicon Pharmaceuticals in the first quarter valued at about $615,000. Virtu Financial LLC bought a new position in Lexicon Pharmaceuticals in the first quarter worth about $105,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at about $912,000. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.